Patients (memory-impaired adults with AD or amnestic mild cognitive impairment vs. control group) were given five intranasal treatment conditions consisting of insulin (10, 20, 40, or 60 IU) or placebo. The gene discussed is INS; the disease is Alzheimer disease.